Navigation Links
Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine
Date:1/8/2014

mean change from baseline in the number of migraine days after 12 weeks of treatment. Topline data are expected in late 2014 to early 2015.

About LBR-101
LBR-101 (formerly RN-307) is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a well validated target in migraine. LBR-101 was originally discovered and developed by Rinat Pharmaceuticals, which was acquired by Pfizer in 2006.  LBR-101 has successfully completed Phase 1 trials with active drug being given to 106 volunteers, results of which were published in Cephalalgia, the official journal of the International Headache Society, in December 2013. Both IV and subcutaneous administrations were extremely well tolerated. LBR-101 exhibited a long terminal half-life ranging from 40 to 48 days, which supports once-monthly dosing. Most treatment related adverse events were mild, transient and resolved spontaneously. The most common TEAEs reported were nasopharyngitis, gastroenteritis and back pain. A maximum tolerated dose has not been identified. LBR-101 was not associated with any clinically relevant patterns of change in vital signs, ECG parameters, or laboratory findings.

LBR-101's long half-life, target specificity and favorable pharmacokinetic profiles, including lack of hepatic metabolism and limited potential for drug interaction may address substantial unmet needs for the prevention of frequent episodic migraines and chronic migraines, a market estimated to be more than 10 million patients in the United States. Proof of efficacy was obtained for several CGRP antagonists in the symptomatic (acute) relief of migraine, yet prophylactic use of those small molecules has been limited by liver toxicity or formulation difficulties. There is only one FDA approved drug for the prevention of chronic migraine (onabotulinumtoxin A), demonstrating the significant
'/>"/>

SOURCE Labrys Biologics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orthobiologics Market (Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others) is Expected to Reach USD 5,519.9 Million Globally in 2019: Transparency Market Research
2. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
3. Crescendo Biologics Raises £17.5M ($28M) in Series A Financing
4. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
5. Synthetic Biologics Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
6. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
7. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
8. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
9. Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
10. Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
11. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® Insulin Pump, today reported its financial results ... In comparing the second quarter of 2014 to the same ... $10.3 million from $5.5 million , t:slim Pump shipments ... In comparing six months ended June 30, 2014 to ...
(Date:7/31/2014)... SUNNYVALE, Calif., July 31, 2014 Pharmacyclics, Inc. (the ... and recent developments for the quarter ended June 30, 2014. ... Ended June 30, 2014 Revenue Total revenue for the ... $54.7 million for the quarter ended June 30, 2013 primarily ... $109.5 million. Total revenue for the six ...
(Date:7/31/2014)... SAN FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... the second quarter ended June 30, 2014. ... were $301.4 million as compared to $309.1 million at March ... time for Nektar as we look forward to significant milestones ... W. Robin, President and Chief Executive Officer of Nektar. "The ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4
... ANDOVER, Mass., June 23, 2011 Smith & Nephew, Inc., ... SNN ) (London Stock Exchange: SN) announced today ... found in Smith & Nephew,s favor that Arthrex, Inc., (Naples, ... exclusively licensed to Smith & Nephew. The ...
... Mr. Ronald L. Chez, a private investor, filed an amended ... RGEN ) with the SEC. RepliGen Corporation ... integrated company by developing and marketing innovative drugs that deliver ... and gastroenterology.  RepliGen has a core competency in the development ...
Cached Medicine Technology:Smith & Nephew Endoscopy Awarded $85 Million in Patent Infringement Case Against Arthrex, Inc. 2Smith & Nephew Endoscopy Awarded $85 Million in Patent Infringement Case Against Arthrex, Inc. 3
(Date:8/2/2014)... On July 21, 2014, the Johns Hopkins Health System ... the class action lawsuit filed October 24, 2013, ... MM, on behalf of thousands of women who allegedly were ... According to The Baltimore Sun , the $190 million ... physician accused of sexual misconduct. , An investigation prompted by ...
(Date:8/1/2014)... August 02, 2014 Although most people ... their teeth and gums, it is particularly important for ... gum disease in two different ways. Hormones can affect ... difficult for these tissues to receive nutrients essential to ... the body responds to toxins produced by plaque bacteria, ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) ... caused strokes, heart attacks, and other injuries in men ... Kennelly as the transferee judge and ordered what could ... court. , As one of his first organizing acts, ... attorneys who will move the litigation forward on behalf ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Parker Waichman ... rights of victims injured by defective medical devices and ... be recalling its Ethicon surgical power morcellator devices used ... sited concerns involving the spread of cancer associated with ... dated July 31, 2014. , Johnson & Johnson ...
(Date:8/1/2014)... Almost 140 people die every year in accidents ... But there are several simple ways to ... coordinator at Cincinnati Children,s Hospital Medical Center,s Comprehensive ... news release. "As families begin to prepare ... parents and children to go over school bus ...
Breaking Medicine News(10 mins):Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 2Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 3Health News:Midtown Dentistry Renews Call for Women to Look After Their Dental Health 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2
... had been in the forefront, monitoring the Herculean task of ... the documentation of the dealers. // This is being done ... is still in safe custody. 20 teams comprising of officials ... with local civic officials. ,The teams will be ...
... in Hong Kong and China have identified the deadly H5N1 ... markets of Southern China, sparking fears of bird flu pandemic//. ... hosts of the bird flu virus. This however is the ... detected among seemingly healthy chickens. Infected chickens usually die within ...
... 'in'? A new report by the American Medical Association has ... wild (s) ways!// ,A survey of 644 female college ... berserk is their take on having fun in life. Three out ... for outrageous behavior- spring break drinking meant bingeing on booze, getting ...
... for a probable influenza pandemic, and its effects on 2.6 ... concern and at a press conference , Health Minister Philippe// ... the beginning of the epidemic we're able to limit the ... plan ready, to face a worst-case possibility, of the initial ...
... It's been a long haul from a medical college here ... becoming the only Indian-born radiologist// licensed to privately practise in ... in his specialty along the way., ,He sees up ... p.m. and then writes up the reports, a task that ...
... means just tough whole-grain products. The movement has burst out ... are available that would have been unthinkable a few years ... whole-grain muesli, rubbery tofu and tasteless vegetarian cutlets, but times ... of Europe today, you will find organic ice cream and ...
Cached Medicine News:Health News:Healthy, Bird Flu Infected Chickens In Chinese Markets 2Health News:Indian-Born Doctor Diddy Shines In Germany 2Health News:Organic food loses its whole-grain image 2
... a two-piece Titanium (Ti-6Al-4V) screw offered in ... variety of lengths. The two pieces are ... packaged. A single instrument set contains all ... both Standard and Mini Kompressor Compression Screws. ...
... Avanta Total Wrist is designed ... in patients suffering from rheumatoid, ... The implant is designed as ... bone resection and aiding in ...
... Within the last decade KMI® revolutionized the ... the Universal Total Wrist System. We're at ... next generation product, the Universal2. Like the ... the way patients live with debilitating arthritis. ...
... NeedlePunch is a simple, effective instrument to grasp ... FiberWire stitch and loop. The grasping function of ... soft tissue and precisely place a stitch up ... the tissue, all in one quick step. The ...
Medicine Products: